Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR -- Ignore unavailable to you. Want to Upgrade?

To: DAN LITTLE who wrote (60)	9/25/2000 7:00:05 PM
From: Bernie Bildman	Read Replies (1) \| Respond to of 278

Has anyone pursued the possibility of putting in an inquiry to Globomax regarding pre-IND meetings?? I wonder if Globomax would answer any email regarding their GENERAL tactics in moving a submission forward (assuming that they will NOT answer any inquiry regarding a specific client)? Would it behoove us to send an email simply asking how they go about moving the process forward and do they use pre-IND meetings?? Anyway, good reporting Dan. Also I assume the note on the Michigan legal case came from ADVR or their PR firm...by the way it was worded it seemed that was the case.

To: DAN LITTLE who wrote (60)	9/25/2000 7:06:38 PM
From: Bernie Bildman	Respond to of 278

I also wonder, in the light of this report, if there is or can be any inquiry as to WHO the FDA advisors are (and their connections - freedom of information act??) that will be determining the future of Product R. This might be a good time to be filing with this light on the FDA. I wonder what Globomax or ADVR's thoughts are on their revelation. By the way, as I am typing this national FOX NEWS is currently running this FDA expose' story, and the FDA refused to appear on camera!! My best bet assumption is that ADVR/Globomax will want to lay low for this IND and not make any waves.